Literature DB >> 10756482

Chemometric rationalization of the structural and physicochemical basis for selective cyclooxygenase-2 inhibition: toward more specific ligands.

E Filipponi1, V Cecchetti, O Tabarrini, D Bonelli, A Fravolini.   

Abstract

The discovery that proinflammatory prostaglandins are produced by cyclooxygenase-2 (COX-2), an inducible isoform of the constitutive cyclooxygenase-1 (COX-1), opened a new frontier in the treatment of inflammatory diseases, because the selective inhibition of COX-2 can lead to therapeutically effective compounds which do not have the common side effects of classical non-steroidal antiinflammatory drugs (NSAIDs). Different crystallographic structures of both free COX-1 and COX-2 as well as complexes with inhibitors have been solved. Because of the great similarity between the two enzymes, it is difficult to detect the most important structural and physicochemical features that would be useful for designing inhibitors with an improved selectivity. In this paper we describe the application of a chemometric procedure to the study of COX-2 selective inhibition. This method, developed to reveal the most suitable regions of isoenzymes for the design of selective ligands, also has a very practical utility. GRID multivariate characterization of the enzymes and subsequent Principal Component Analysis (PCA) of the descriptor variables allow the identification of chemical groups that could be added to a core template structure to increase ligand selectivity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10756482     DOI: 10.1023/a:1008180108753

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  31 in total

1.  Discovery of a new cyclooxygenase-2 lead compound through 3-D database searching and combinatorial chemistry.

Authors:  K D Stewart; S Loren; L Frey; E Otis; V Klinghofer; K I Hulkower
Journal:  Bioorg Med Chem Lett       Date:  1998-03-03       Impact factor: 2.823

2.  Interactions of some PGHS-2 selective inhibitors with the PGHS-1: an automated docking study by BioDock.

Authors:  A Pedretti; A M Villa; L Villa; G Vistoli
Journal:  Farmaco       Date:  1997 Jun-Jul

3.  Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2.

Authors:  C Luong; A Miller; J Barnett; J Chow; C Ramesha; M F Browner
Journal:  Nat Struct Biol       Date:  1996-11

4.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.

Authors:  R G Kurumbail; A M Stevens; J K Gierse; J J McDonald; R A Stegeman; J Y Pak; D Gildehaus; J M Miyashiro; T D Penning; K Seibert; P C Isakson; W C Stallings
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

5.  A novel strategy for improving ligand selectivity in receptor-based drug design.

Authors:  M Pastor; G Cruciani
Journal:  J Med Chem       Date:  1995-11-10       Impact factor: 7.446

6.  Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents.

Authors:  Q Guo; L H Wang; K H Ruan; R J Kulmacz
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

7.  Human cyclooxygenase-2 cDNA.

Authors:  T Hla; K Neilson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Authors:  J L Masferrer; B S Zweifel; P T Manning; S D Hauser; K M Leahy; W G Smith; P C Isakson; K Seibert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.

Authors:  N Futaki; S Takahashi; M Yokoyama; I Arai; S Higuchi; S Otomo
Journal:  Prostaglandins       Date:  1994-01

10.  Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor.

Authors:  K R Gans; W Galbraith; R J Roman; S B Haber; J S Kerr; W K Schmidt; C Smith; W E Hewes; N R Ackerman
Journal:  J Pharmacol Exp Ther       Date:  1990-07       Impact factor: 4.030

View more
  3 in total

1.  Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.

Authors:  Bernard Pirard
Journal:  J Comput Aided Mol Des       Date:  2003-11       Impact factor: 3.686

2.  Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis.

Authors:  Giuseppe Ermondi; Giulia Caron; Raelene Lawrence; Dario Longo
Journal:  J Comput Aided Mol Des       Date:  2004-11       Impact factor: 3.686

3.  Structure-based QSAR study on differential inhibition of human prostaglandin endoperoxide H synthase-2 (COX-2) by nonsteroidal anti-inflammatory drugs.

Authors:  R Pouplana; J J Lozano; C Pérez; J Ruiz
Journal:  J Comput Aided Mol Des       Date:  2002-10       Impact factor: 3.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.